Cas:39891-71-9 methyl 2,3-dihydro-1H-indole-3-carboxylate manufacturer & supplier

We serve Chemical Name:methyl 2,3-dihydro-1H-indole-3-carboxylate CAS:39891-71-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

methyl 2,3-dihydro-1H-indole-3-carboxylate

Chemical Name:methyl 2,3-dihydro-1H-indole-3-carboxylate
CAS.NO:39891-71-9
Synonyms:2,3-DIBROMO-1,1,3,3-TETRAFLUOROPROPENE-1;2,3-dihydro-indole-3-carboxylic acid methyl ester;methyl indoline-3-carboxylate
Molecular Formula:C10H11NO2
Molecular Weight:177.20000
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:38.33000
Exact Mass:177.07900
LogP:1.50670

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2,3-DIBROMO-1,1,3,3-TETRAFLUOROPROPENE-1 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl indoline-3-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3-DIBROMO-1,1,3,3-TETRAFLUOROPROPENE-1 Use and application,2,3-DIBROMO-1,1,3,3-TETRAFLUOROPROPENE-1 technical grade,usp/ep/jp grade.


Related News: Roche’s second anti-tau antibody UCB0107, partnered with UCB, is also slated to enter deeper testing this year. Tau had appeared to have fresh promise as a rival of sorts to amyloid. Tau theory goes that neurofibrillary tangles that form inside cells clog up the brain, and clearing this can help Alzheimer’s patients. methyl 2,3-dihydro-1H-indole-3-carboxylate manufacturer Our pharma and biotech offering includes registration and commercialization of products through in-licensing and flexible partnerships. methyl 2,3-dihydro-1H-indole-3-carboxylate supplier This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? methyl 2,3-dihydro-1H-indole-3-carboxylate vendor The death toll in China rose to at least 304. methyl 2,3-dihydro-1H-indole-3-carboxylate factory The death toll in China rose to at least 304.